Will the FDA approve baxdrostat for hard-to-control hypertension? Odds & Predictions

MARKETS LIVE24 SOCIAL

Cash

Portfolio

Search

Trending Elections Politics Sports Culture Crypto Commodities Climate Economics Mentions Companies Financials Tech & Science

Portfolio

Search

Company

Blog Careers Privacy Policy Data Terms of Service Company Brand Kit

Social

X (Twitter)LinkedIn Discord Instagram Reddit TikTok

Product

Help Center API FAQ FAQ for Finance Professionals Regulatory Trading Hours Fee Schedule Trading Prohibitions Incentive Program Research Institutional Trading Responsible Trading Market Integrity

© 2026 Kalshi Inc.

Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.

Trending Elections Politics Sports Culture Crypto Commodities Climate Economics Mentions Companies Financials Tech & Science

Will the FDA approve baxdrostat for hard-to-control hypertension? Odds & Predictions